JPRN-UMIN000038604已完成未知
Efficacy and safety of Ledipasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 2 Infection - Harvoni in Genotype 2 HCV patients
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 126
研究概览
简要总结
The overall SVR rates of the ITT and mITT populations were 87.3% (95% confidence interval [CI] 80.2-92.6) (110/126) and 97.3% (95% CI 92.4-99.4) (110/113), respectively. In the mITT population, the percentages of patients with undetectable HCV RNA at 4, 8, and 12 weeks after the start of therapy were 92.9% (95% CI 86.5-96.9) (105/113), 99.1% (95% CI 95.2-100.0) (112/113), and 100.0% (95% CI 97.4-100.0) (113/113), respectively.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Prior exposure to a direct-acting antiviral agent targeting HCV NS5A or NS5B Decompensated cirrhosis Creatinine clearance (Cockcroft-Gault) less than 30 mL/min
研究者
相似试验
已完成
2 期
Efficacy and safe of Ledipasvir/Sofosbuvir with Ribavirin in Patients who failed Daclatasvir/Asunaprevir with chronic hepatitis C-multicenter,pilot studyJPRN-UMIN000021969Hiroshima liver study group30
招募中
不适用
Efficacy and safety of Sofosbuvir / Velpatasvir combination therapy for type C decompensated cirrhosistype C decompensated cirrhosisJPRN-UMIN000038587ippon Medical School, Division of Gastroenterology and Hepatology, Department of Internal Medicine400
尚未招募
不适用
Efficacy and safety of ledipasvir and sofosbuvir in patients with chronic hepatitis CPatients with chronic hepatitis C virus infectionJPRN-UMIN000018561Osaka University Graduate School of Medicine, Department of Gastroenterology and Hepatology2,000
已完成
2 期
on-randomized clinical trial of the efficacy of Ledipasvir and Sofosbuvir in children with genotype 1 hepatitis C virus infectiochronic hepatitis CB182JPRN-jRCTs051180110Tajiri Hitoshi2
已完成
不适用
Efficacy and safety of ledipasvir/sofosubuvir/ribavirin combination therapy for failures to daculatasvir/asunaprevir combination therapy.Patients infected with HCV genotype 1, who failed to daculatasvir/asunaprevir comnination therapy.JPRN-UMIN000022418Toranomon Hospital, Department of Hepatology.20